Acrongenomics utilizes its extensive international network and qualified management team to scout out and invest in dynamic research projects. To that extent Acrongenomics has established a Strategic Alliance with the UK based Molecular Vision Ltd after completing a joint venture development agreement worth $6.5 Million U.S.

About Molecular Vision Ltd

Molecular Vision is a spin-out company of Imperial Innovations Ltd. The company was founded in 2002 in order to meet a clearly defined demand in the medical diagnostics, biosensors and analytical instrumentations markets: the need for miniaturized chemical and biological detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets.

Pearson Matthews is a specialist design development company with 20 years experience specifically in the healthcare sector for companies in the UK, US and Europe. Started in 1983 by Mike Pearson, they have built a reputation around innovation and the development of breakthrough products. Pearson Matthews is ISO9001 accredited, giving it the ability to handle major projects from early R&D through to manufacture.

 

About the Health Technology Devices Scheme

The Health Technology Devices Scheme was set up by the UK National Health Service (NHS) to stimulate, commission and monitor collaborative R&D on innovative new health technology devices that would improve the health and wealth of the UK. The aim of the scheme is to facilitate links between companies, science-based researchers, NHS professionals and patient consumer groups in order to deliver innovative medical and technological devices that assist implementation of the NHS.